title: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
abstract: Benign prostatic hyperplasia (BPH) is a complex and progressive disease common in aging men. While associated with bothersome lower urinary tract symptoms, it may also result in additional serious complications such as refractory hematuria, acute urinary retention, and BPH-related surgery. Medical therapy has been offered as an approach to halt this progression and perhaps reverse the pathophysiology of BPH. While alpha-blockers provide rapid relief in the form of improved flow rate, their effects may not reduce the overall risk of BPH-related complications. 5alpha-reductase inhibitors were therefore introduced to affect the underlying disease process by inhibiting the enzyme which converts testosterone to dihydrotesterone, the primary androgen involved in normal and abnormal prostate growth. Through this inhibition, prostate size is decreased, thereby reducing the risk of acute urinary retention and BPH-related surgery while providing symptom control. These effects are most pronounced in men with enlarged prostates (>25 mL) who are at the greatest risk of disease progression. This article reviews the literature for finasteride used in the treatment of BPH and provides evidence for its efficacy, safety and tolerability, applicability for combination therapy, and considerations of its effects on prostate cancer risk.
authors.affiliation: University of North Carolina Division of Urologic Surgery, Chapel Hill, NC, USA.
authors.forename: Angela B
authors.initials: AB
authors.lastname: Smith
authors.forename: Culley C
authors.initials: CC
authors.lastname: Carson
references.citation: Prostate Cancer Prostatic Dis. 2005;8(3):215-8
references.pmid: 15999118
references.citation: J Urol. 2008 Jun;179(6):2333-8
references.pmid: 18423697
references.citation: BMC Clin Pharmacol. 2006 Oct 07;6:7
references.pmid: 17026771
references.citation: Urol Int. 2008;80(2):177-80
references.pmid: 18362489
references.citation: J Urol. 2009 Apr;181(4):1642-57
references.pmid: 19249063
references.citation: Urology. 1998 Aug;52(2):195-201; discussion 201-2
references.pmid: 9697781
references.citation: Eur Urol. 2001 Apr;39(4):390-9
references.pmid: 11306876
references.citation: Urology. 1995 Nov;46(5):631-7
references.pmid: 7495111
references.citation: J Urol. 1995 Oct;154(4):1466-9
references.pmid: 7544845
references.citation: J Urol. 2006 Jan;175(1):217-20; discussion 220-1
references.pmid: 16406915
references.citation: Cancer Prev Res (Phila). 2008 Aug;1(3):174-81
references.pmid: 19138953
references.citation: Prostate. 1992;21(3):247-54
references.pmid: 1279647
references.citation: J Urol. 2000 Feb;163(2):496-8
references.pmid: 10647664
references.citation: Urology. 2003 Jan;61(1):119-26
references.pmid: 12559281
references.citation: Urology. 1994 Mar;43(3):284-92; discussion 292-4
references.pmid: 7510911
references.citation: J Urol. 1993 Feb;149(2):342-4
references.pmid: 7678871
references.citation: Urology. 1996 Sep;48(3):398-405
references.pmid: 8804493
references.citation: J Urol. 1993 Nov;150(5 Pt 2):1736-9
references.pmid: 7692110
references.citation: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091
references.pmid: 18425978
references.citation: Cancer. 2008 Mar 1;112(5):1058-65
references.pmid: 18186497
references.citation: J Sex Med. 2007 Nov;4(6):1708-12
references.pmid: 17655657
references.citation: Eur Urol. 1998 Sep;34(3):169-75
references.pmid: 9732187
references.citation: BJU Int. 2005 Dec;96(9):1319-22
references.pmid: 16287453
references.citation: Prostate. 1993;22(1):31-7
references.pmid: 7678930
references.citation: Prostate. 1993;22(4):291-9
references.pmid: 7684524
references.citation: Urology. 1998 Feb;51(2):237-40
references.pmid: 9495704
references.citation: Annu Rev Biochem. 1994;63:25-61
references.pmid: 7979239
references.citation: J Natl Cancer Inst. 2007 Jul 4;99(13):1025-35
references.pmid: 17596576
references.citation: J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83
references.pmid: 17848673
references.citation: N Engl J Med. 1992 Oct 22;327(17):1185-91
references.pmid: 1383816
references.citation: N Engl J Med. 2003 Dec 18;349(25):2387-98
references.pmid: 14681504
references.citation: J Clin Invest. 1992 Jan;89(1):293-300
references.pmid: 1345916
references.citation: N Engl J Med. 1998 Feb 26;338(9):557-63
references.pmid: 9475762
references.citation: Prostate. 1997 May 15;31(3):180-2
references.pmid: 9167770
references.citation: Cancer Prev Res (Phila). 2008 Aug;1(3):167-73
references.pmid: 19138952
references.citation: N Engl J Med. 1996 Aug 22;335(8):533-9
references.pmid: 8684407
references.citation: Eur Urol. 2003 Oct;44(4):461-6
references.pmid: 14499682
references.citation: Scand J Urol Nephrol. 2007;41(2):124-31
references.pmid: 17454951
references.citation: Am J Health Syst Pharm. 2003 Aug 1;60(15):1511, 1515
references.pmid: 12951749
references.citation: J Urol. 1995 Nov;154(5):1779-82
references.pmid: 7563345
references.citation: Int J Clin Pract. 2008 Jul;62(7):1076-86
references.pmid: 18479366
references.citation: Urology. 2003 Apr;61(4 Suppl 1):2-7
references.pmid: 12657354
references.citation: J Urol. 1998 Oct;160(4):1358-67
references.pmid: 9751354
references.citation: Urology. 1999 Apr;53(4):690-5
references.pmid: 10197842
references.citation: Trans Am Assoc Genitourin Surg. 1976;68:29-32
references.pmid: 71777